This is a news story, published by Sky News, that relates primarily to Lecanemab news.
For more Lecanemab news, you can click here:
more Lecanemab newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Sky News, you can click here:
more news from Sky NewsOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Alzheimer. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest expensive PET brain scans news, NHS spending watchdog news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
lecanemabSky News
•
74% Informative
Lecanemab is a potent drug that can slow the decline in memory and thinking.
It clears the clumps of abnormal protein called amyloid that build up in the brains of people with Alzheimer's.
But in doing so it can sometimes cause dangerous swelling and bleeding in the brain.
The NHS spending watchdog has ruled it is too expensive to justify the benefits.
VR Score
73
Informative language
70
Neutral language
64
Article tone
informal
Language
English
Language complexity
37
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links